Abstract: Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.

Abstract: Multigraft copolymers having various structures, e.g., comb and centipede structures, can be prepared from emulsion copolymerization of monomers and macromonomers. The emulsion copolymerization can be initiated by a thermally activated radical initiator or a redox initiation system. The multigraft copolymers can have high molecular weight and/or a large number of branch points. Elastomer or adhesive compositions of the copolymers can be prepared. Also described are poly(n-alkyl acrylate-graft-styrene) multigraft copolymers.

Abstract: Immunoglobulin light chain proteins are used to generate synthetic fibrils in vitro. The fibrils are mixed with immunoglobulin light chain proteins from a biological sample. In either a direct binding assay, competition assay, or dilution-based competition assay, a signal is detected from the mixture. The intensity of the detectable signal relates to the level of binding between the immunoglobulin light chain proteins to the fibrils and can thus be used to identify amyloidogenic immunoglobulin light chain proteins in a biological sample of the subject and to assess amyloidogenic risk to a subject. For example, the signal intensities from the assays can be used in a comparison to one or more threshold (control) values derived from samples of known light chain types or in the absence of light chains. The comparisons permit identification of amyloidogenic proteins, assessment of amyloidogenic risk, and categorization of the subject into an appropriate “at risk” group.

Abstract: A synchrophasor measurement method for a device configured to take synchronized measurements in a power system is provided. The synchrophasor measurement method includes receiving global positioning system (GPS)-synchronized samples of a signal sensed by the device from the power system; determining a level of distortion of the signal; selecting, based on the level of distortion, a computation method, the computation method being one of an improved zero-crossing (IZC) method and an enhanced phase-lock-loop (EPLL) method; performing the selected computation method to determine at least one parameter of the signal at a reporting frequency, which is at least twice a line frequency of the power system; and outputting, at the reporting frequency, the at least one parameter to an operator of the power system to allow the operator to perform at least one of a monitoring and a controlling of at least one element of the power system.

Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: Microwave AC conductivity may be improved or tuned in a material, for example, a dielectric or semiconductor material, by manipulating domain wall morphology in the material. Domain walls may be created, erased or reconfigured to control the AC conductivity, for example, for crafting circuit elements. The density and placement of domain walls may increase or decrease the AC conductivity and may control AC conduction pathways through the material. An electric potential applied to the material's surface may create a desired pattern of domain walls to meet desired AC conductivity criteria. Incline angle of the domain walls may be modified relative to a crystallographic axis of the material to temporarily or permanently modify or gate AC conductivity of the material. For example, the AC conductivity of the material may be gated by domain wall incline angle to increase, decrease or throttle current flowing through the material for an electronic circuit element.

Abstract: A molecule that binds specifically to a human tissue plasminogen activator (TPA) or a TPA mutant is provided. The molecule having sub-nanomolar affinity to inhibit fibrin-dependent plasminogen activation with an IC50<5 nM, to inhibit degradation of human fibrin clots without affecting TPA amidolytic activity or non-fibrin-dependent activation, and the amino acid sequence of the TPA mutant is at least 65% identical to SEQ ID NO: 1 or SEQ ID NO: 2. Further provided is a method for treating systemic bleeding and brain hemorrhage after TPA treatment in a patient in need of such treatment. The method comprises administering to said patient an effective amount of the molecule, wherein the molecule selectively inhibits fibrin-augmented plasminogen activation in the patient.

Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.

Abstract: The present invention relates to colchicine-binding site compounds having anti-cancer activity, compositions comprising the same, and their use for treating various forms of cancer.

Abstract: A synchrophasor measurement method for a device configured to take synchronized measurements in a power system is provided. The synchrophasor measurement method includes receiving global positioning system (GPS)-synchronized samples of a signal sensed by the device from the power system; determining a level of distortion of the signal; selecting, based on the level of distortion, a computation method, the computation method being one of an improved zero-crossing (IZC) method and an enhanced phase-lock-loop (EPLL) method; performing the selected computation method to determine at least one parameter of the signal at a reporting frequency, which is at least twice a line frequency of the power system; and outputting, at the reporting frequency, the at least one parameter to an operator of the power system to allow the operator to perform at least one of a monitoring and a controlling of at least one element of the power system.

Abstract: A method for determining a location of a disturbance in a power system is provided. The method includes receiving data from a plurality of sensors distributed across the power system; performing a recurrence quantification analysis on the received data to identify a predetermined number of sensors, from the plurality of sensors, that are closest to the disturbance; constructing a plurality of minimum-volume-enclosing ellipsoids based on and enclosing the data received from the identified sensors; extracting one or more parameters from the plurality of minimum-volume-enclosing ellipsoids; inputting the one or more parameters into a multivariate-random-forest regression algorithm to determine the location of the disturbance and a power mismatch corresponding to the disturbance; and presenting, on one or more display units, the determined location of the disturbance and the determined power mismatch.

Abstract: A comprehensive process for treating lignocellulosic biomass in order to separate the biomass into its component parts, the process comprising: a) contacting the lignocellulosic biomass with a first solvent for a period of time and at a first temperature at a severity in the range of about 2 to about 4 to remove extractive components and a portion of ash from the biomass; b) contacting the biomass from step (a) with a second solvent, and optional catalyst, at a second temperature at a severity in the range of about 1 to 5 to remove hemicelluloses and additional ash from the biomass; and c) separating the biomass from step (b) into a lignin product and a cellulose product by contacting the biomass from step (b) with a third solvent at a severity in the range of about 1.5 to 5 to provide a spent liquor product and a solid fraction containing cellulose.

Abstract: The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

Abstract: The present disclosure relates to additives used in conjunction with adhesives to give enhanced performance. Engineered composite wood materials and methods of making such materials are also provided by the subject application. A reinforced adhesive includes an adhesive and an additive material comprising nanoscopic and microscopic materials.

Abstract: A circuit element of a multi-dimensional dynamic adaptive neural network array (DANNA) may comprise a neuron/synapse select input functional to select the circuit element to function as one of a neuron and a synapse. In one embodiment of a DANNA array of such circuit elements, (wherein a circuit element or component thereof may be analog or digital), a destination neuron may be connected to a first neuron by a first synapse in one dimension, a second destination neuron may be connected to the first neuron by a second synapse in a second dimension and, optionally, a third destination neuron may be connected to the first neuron by a third synapse. The DANNA may thus form multiple levels of neuron and synapse circuit elements. In one embodiment, multiples of eight inputs may be selectively received by the circuit element selectively functioning as one of a neuron and a synapse.

Abstract: This invention provides novel 3-amino propanamide selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.